Roche picks up a new autoimmune drug with $580M Adheron deal

10-9 – BWH spinout and PIF portfolio company, Adheron, has been acquired by Roch. Adheron is developing antibodies (currently in Phase I) targeting cadherin-11 for treatment of rheumatoid arthritis and other indications, and is based on technology developed by Michael Brenner, MD at BWH. Roche will be a great partner to move the product forward into Phase II trials and hopefully to market. The total deal value is $580 million, with $105 million paid on closing.
The initial payout will be approximately $5.2 million for PIF (for our $1.3 million investment) and $473K for BWH from the license (subject to patent policy splits). The total payout over time could reach $32 million for PIF and $5 million for BWH if all milestones are reached, with the next major milestone being a positive Phase II trial.

http://www.prnewswire.com/news-releases/adheron-therapeutics-to-be-acquired-by-roche-300156996.html

Most Recent Posts:

Ten Projects Advance at 4th Annual MESH Innovation Teams’ ‘Problem Day’

Top Finalists to Enter Yearlong Program Guiding Their Innovations Aimed at Enhancing Patient Care   It’s surely…

Read More
Khurana BWH

New Study Finds Holidays as Peak Times for Domestic Violence Injuries

Research aids in developing AI aimed at early detection   Breaking the cycle of intimate partner violence…

Read More
Blog Innovation Grand Rounds Yu image

Innovation Grand Rounds: Genetics, Signaling, and Academic Discovery as Gateways to Drug Development

Innovation Grand Rounds is a monthly live series with talks by innovators and executives from across the…

Read More